Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.8
5.6
Journals
IJMS
Special Issues
Cell Therapy for Parkinson's Disease
ijms-logo
Submit to IJMS Review for IJMS Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Cell Therapy for Parkinson's Disease

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".

Deadline for manuscript submissions: closed (30 September 2023) | Viewed by 4940

Special Issue Editors

Dr. Jannette Rodríguez-Pallares

E-Mail Website
Guest Editor
1. Laboratory of Neuroanatomy and Experimental Neurology, Department of Morphological Sciences, CIMUS, University of Santiago de Compostela, 15782 Santiago de Compostela, Spain
2. Networking Research Center on Neurodegenerative Diseases (CIBERNED), 28029 Madrid, Spain
Interests: neuroscience; neurodegeneration; neuroprotection; cell therapy; Parkinson's disease
Special Issues, Collections and Topics in MDPI journals
Prof. Dr. Juan A. Parga

E-Mail Website
Guest Editor
Laboratory of Neuroanatomy and Experimental Neurology, Department of Morphological Sciences, CIMUS, Universidade de Santiago de Compostela, Galicia, Spain
Interests: human induced pluripotent stem cells; neurodegeneration; nrf2/are signaling; Parkinson's disease; stem cells

Special Issue Information

Dear Colleagues,

We are delighted to announce that the Special Issue titled “Cell therapy for Parkinson’s disease” is now open to receiving proposals.

More than two centuries since Parkinson’s disease was first described as ‘shaking palsy’ by James Parkinson, many advances have been made regarding pathophysiology knowledge and symptomatic treatments. However, there is still no cure for the disease, and important issues remain unresolved; therefore, the need to change the progression of the disease is a priority.

Cell therapy offers a complete paradigm shift from current treatments, as this approach holds the potential to stop or even reverse the progression of the disease. Pioneering preclinical studies on dopaminergic transplants and decades of advances in neuron regeneration paved the way for considering cell-based therapies suitable for clinical translation. The field is now entering a new phase where clinical-grade products based on pluripotent stem cells are being trialled in patients. Moreover, the development of potential new therapies, based on tissue engineering and gene therapy, is really breaking new ground in the field. Despite the encouraging results obtained in preclinical studies, translational application of these therapies has not been at the desired level and further studies are undoubtedly needed.

The aim of this Special Issue is to broaden the knowledge on the use of regenerative medicine, especially focused on innovative cell therapy strategies, as potential approaches for the treatment of Parkinson’s disease.

We invite basic and clinical investigators to present their valuable work either as original articles(s) or review(s) to this Special Issue. We are highly grateful for your contributions, and consider it a pleasure to get to receive your manuscripts.

Prof. Dr. Jannette Rodríguez-Pallares
Prof. Dr. Juan A. Parga
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Parkinson’s disease
  • cell therapy
  • stem cells
  • neurorepair
  • cell transplantation
  • regenerative medicine
  • cellular reprogramming
  • cell survival/differentiation
  • cellular/molecular mechanisms
  • immunomodulation
  • neurotrophic factors
  • neurogenesis
  • gene therapy
  • tissue engineering
  • brain organoids

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

12 pages, 1390 KiB  
Communication
Protection and Repair of the Nigrostriatal Pathway with Stem-Cell-Derived Carotid Body Glomus Cell Transplants in Chronic MPTP Parkinsonian Model
by Javier Villadiego, Ana B. Muñoz-Manchado, Verónica Sobrino, Victoria Bonilla-Henao, Nela Suárez-Luna, Patricia Ortega-Sáenz, Ricardo Pardal, José López-Barneo and Juan J. Toledo-Aral
Int. J. Mol. Sci. 2023, 24(6), 5575; https://doi.org/10.3390/ijms24065575 - 14 Mar 2023
Cited by 2 | Viewed by 1580
Abstract
Antiparkinsonian carotid body (CB) cell therapy has been proven to be effective in rodent and nonhuman primate models of Parkinson’s disease (PD), exerting trophic protection and restoration of the dopaminergic nigrostriatal pathway. These neurotrophic actions are mediated through the release of high levels [...] Read more.
Antiparkinsonian carotid body (CB) cell therapy has been proven to be effective in rodent and nonhuman primate models of Parkinson’s disease (PD), exerting trophic protection and restoration of the dopaminergic nigrostriatal pathway. These neurotrophic actions are mediated through the release of high levels of glial-cell-line-derived neurotrophic factor (GDNF) by the CB transplant. Pilot clinical trials have also shown that CB autotransplantation can improve motor symptoms in PD patients, although its effectiveness is affected by the scarcity of the grafted tissue. Here, we analyzed the antiparkinsonian efficacy of in vitro-expanded CB dopaminergic glomus cells. Intrastriatal xenografts of rat CB neurospheres were shown to protect nigral neurons from degeneration in a chronic MPTP mouse PD model. In addition, grafts performed at the end of the neurotoxic treatment resulted in the repair of striatal dopaminergic terminals through axonal sprouting. Interestingly, both neuroprotective and reparative effects induced by in vitro-expanded CB cells were similar to those previously reported by the use of CB transplants. This action could be explained because stem-cell-derived CB neurospheres produce similar amounts of GDNF compared to native CB tissue. This study provides the first evidence that in vitro-expanded CB cells could be a clinical option for cell therapy in PD. Full article
(This article belongs to the Special Issue Cell Therapy for Parkinson's Disease)
►▼ Show Figures

Figure 1

Review

Jump to: Research

18 pages, 718 KiB  
Review
Sequestration of Inflammation in Parkinson’s Disease via Stem Cell Therapy
by Jonah Gordon, Gavin Lockard, Molly Monsour, Adam Alayli, Hassan Choudhary and Cesario V. Borlongan
Int. J. Mol. Sci. 2022, 23(17), 10138; https://doi.org/10.3390/ijms231710138 - 4 Sep 2022
Cited by 3 | Viewed by 2466
Abstract
Parkinson’s disease is the second most common neurodegenerative disease. Insidious and progressive, this disorder is secondary to the gradual loss of dopaminergic signaling and worsening neuroinflammation, affecting patients’ motor capabilities. Gold standard treatment includes exogenous dopamine therapy in the form of levodopa–carbidopa, or [...] Read more.
Parkinson’s disease is the second most common neurodegenerative disease. Insidious and progressive, this disorder is secondary to the gradual loss of dopaminergic signaling and worsening neuroinflammation, affecting patients’ motor capabilities. Gold standard treatment includes exogenous dopamine therapy in the form of levodopa–carbidopa, or surgical intervention with a deep brain stimulator to the subcortical basal ganglia. Unfortunately, these therapies may ironically exacerbate the already pro-inflammatory environment. An alternative approach may involve cell-based therapies. Cell-based therapies, whether endogenous or exogenous, often have anti-inflammatory properties. Alternative strategies, such as exercise and diet modifications, also appear to play a significant role in facilitating endogenous and exogenous stem cells to induce an anti-inflammatory response, and thus are of unique interest to neuroinflammatory conditions including Parkinson’s disease. Treating patients with current gold standard therapeutics and adding adjuvant stem cell therapy, alongside the aforementioned lifestyle modifications, may ideally sequester inflammation and thus halt neurodegeneration. Full article
(This article belongs to the Special Issue Cell Therapy for Parkinson's Disease)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop